Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers.

Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim TS, Choi SJ, Kim HD, Han JW, Kwon M, Kim JH, Lee AJ, Nam SK, Bae SJ, Lee SB, Shin SJ, Park SH, Ahn JB, Jung I, Lee KY, Park SH, Kim H, Min BS, Shin EC.

Sci Immunol. 2019 Nov 8;4(41). pii: eaay0555. doi: 10.1126/sciimmunol.aay0555.

PMID:
31704735
2.

Objectively measured physical activity during chemotherapy in colon cancer patients.

Park H, Jung M, Kim MJ, Min J, Lee CK, Shin SJ, Beom SH, Ahn JB, Jeon JY.

Support Care Cancer. 2019 Oct 14. doi: 10.1007/s00520-019-05049-9. [Epub ahead of print]

PMID:
31612283
3.

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.

Hong YS, Kim SY, Lee JS, Nam BH, Kim KP, Kim JE, Park YS, Park JO, Baek JY, Kim TY, Lee KW, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.

J Clin Oncol. 2019 Nov 20;37(33):3111-3123. doi: 10.1200/JCO.19.00016. Epub 2019 Oct 8.

PMID:
31593484
4.

Treatment Outcomes of Re-irradiation in Locoregionally Recurrent Rectal Cancer and Clinical Significance of Proper Patient Selection.

Chung SY, Koom WS, Keum KC, Chang JS, Shin SJ, Ahn JB, Min BS, Lee KY, Kim NK, Yoon HI.

Front Oncol. 2019 Jun 19;9:529. doi: 10.3389/fonc.2019.00529. eCollection 2019.

5.

Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process.

Ahn JB, Kim DH, Lee SE, Pyo YC, Park JS.

Int J Pharm. 2019 Jun 10;564:263-272. doi: 10.1016/j.ijpharm.2019.04.051. Epub 2019 Apr 20.

PMID:
31015003
6.

Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors.

Park JS, Kang B, Park Y, Park SJ, Cheon JH, Jung M, Beom SH, Shin SJ, Hur H, Min BS, Baik SH, Lee KY, Ahn JB, Kim NK, Kim TI.

J Cancer Prev. 2019 Mar;24(1):48-53. doi: 10.15430/JCP.2019.24.1.48. Epub 2019 Mar 30.

7.

Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability.

Byeon JC, Lee SE, Kim TH, Ahn JB, Kim DH, Choi JS, Park JS.

Drug Deliv. 2019 Dec;26(1):216-225. doi: 10.1080/10717544.2018.1551441.

8.

Assimilating MODIS data-derived minimum input data set and water stress factors into CERES-Maize model improves regional corn yield predictions.

Ban HY, Ahn JB, Lee BW.

PLoS One. 2019 Feb 25;14(2):e0211874. doi: 10.1371/journal.pone.0211874. eCollection 2019.

9.

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.

Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C.

Clin Cancer Res. 2019 Mar 1;25(5):1612-1623. doi: 10.1158/1078-0432.CCR-18-1932. Epub 2018 Dec 11.

PMID:
30538109
10.

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.

Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK.

Cancer Res Treat. 2019 Jul;51(3):1128-1134. doi: 10.4143/crt.2018.379. Epub 2018 Nov 21.

11.

Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats.

Choi JS, Ahn JB, Park JS.

Int J Pharm. 2019 Jan 30;555:135-145. doi: 10.1016/j.ijpharm.2018.11.050. Epub 2018 Nov 17.

PMID:
30458259
12.

Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.

Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, Kim SH, Hur H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim HS.

Oncology. 2019;96(2):59-69. doi: 10.1159/000492597. Epub 2018 Oct 18.

PMID:
30336470
13.

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.

Kim SH, Ryu H, Ock CY, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Bang SM, Kim JH, Lee JS, Ahn JB, Kim KJ, Rha SY.

Int J Mol Sci. 2018 Oct 15;19(10). pii: E3164. doi: 10.3390/ijms19103164.

14.

A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.

Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, Kim BG, Lee KW, Kim JW, Oh HS, Ahn JB, Zang DY, Kim DY, Oh JH, Baek JY.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899. doi: 10.1016/j.ijrobp.2018.04.013. Epub 2018 Apr 12.

PMID:
29976501
15.

The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.

Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY.

Gastric Cancer. 2019 Jan;22(1):113-122. doi: 10.1007/s10120-018-0847-5. Epub 2018 Jun 9.

16.

CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.

Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Ahn JB.

Yonsei Med J. 2018 Jul;59(5):588-594. doi: 10.3349/ymj.2018.59.5.588.

17.

T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer.

Kim S, Han K, Seo N, Kim HJ, Kim MJ, Koom WS, Ahn JB, Lim JS.

Eur Radiol. 2018 Dec;28(12):5231-5240. doi: 10.1007/s00330-018-5520-1. Epub 2018 Jun 1.

PMID:
29858637
18.

Deep Resequencing of Ulcerative Colitis-Associated Genes Identifies Novel Variants in Candidate Genes in the Korean Population.

Moon CM, Kim SW, Ahn JB, Ma HW, Che X, Kim TI, Kim WH, Cheon JH.

Inflamm Bowel Dis. 2018 Jul 12;24(8):1706-1717. doi: 10.1093/ibd/izy122.

PMID:
29733354
19.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.

Kim TW, Elme A, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Manojlovic N, Guan X, Lofton-Day C, Jung AS, Vrdoljak E.

Clin Colorectal Cancer. 2018 Sep;17(3):206-214. doi: 10.1016/j.clcc.2018.03.008. Epub 2018 Mar 21.

20.

Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection.

Kim C, Kim WR, Kim KY, Chon HJ, Beom SH, Kim H, Jung M, Shin SJ, Kim NK, Ahn JB.

Clin Colorectal Cancer. 2018 Sep;17(3):e513-e518. doi: 10.1016/j.clcc.2018.03.011. Epub 2018 Mar 29.

PMID:
29661621
21.

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.

Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.

PMID:
29555258
22.

Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective.

Choi SH, Chang JS, Yoon HI, Jang DS, Kim NK, Lim JS, Min BS, Huh H, Shin SJ, Ahn JB, Koom WS.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1119-1128. doi: 10.1007/s00432-018-2624-6. Epub 2018 Mar 15.

PMID:
29546480
23.

Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.

Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS.

BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.

24.

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.

Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J.

J Clin Oncol. 2018 Feb 1;36(4):350-358. doi: 10.1200/JCO.2017.74.3245. Epub 2017 Dec 7.

PMID:
29215955
25.

The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.

Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS.

Korean J Intern Med. 2019 Jan;34(1):165-177. doi: 10.3904/kjim.2016.348. Epub 2017 Nov 28.

26.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
27.

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.

Kim CG, Ahn JB, Shin SJ, Beom SH, Heo SJ, Park HS, Kim JH, Choe EA, Koom WS, Hur H, Min BS, Kim NK, Kim H, Kim C, Jung I, Jung M.

BMC Cancer. 2017 Sep 2;17(1):615. doi: 10.1186/s12885-017-3624-7.

28.

Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Jeung HC, Rha SY, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC.

Oncol Lett. 2017 Aug;14(2):2385-2392. doi: 10.3892/ol.2017.6438. Epub 2017 Jun 21.

29.

Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.

Kim Y, Park SE, Moon JW, Kim BM, Kim HG, Jeong IG, Yoo S, Ahn JB, You D, Pak JH, Kim S, Hwang JJ, Kim CS.

Prostate. 2017 Jul;77(10):1128-1136. doi: 10.1002/pros.23370. Epub 2017 May 30.

PMID:
28556958
30.

A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.

Kim GM, Reid T, Shin SJ, Rha SY, Ahn JB, Lee SS, Chung HC.

Invest New Drugs. 2017 Dec;35(6):773-781. doi: 10.1007/s10637-017-0460-1. Epub 2017 Mar 28.

PMID:
28353123
31.

Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancer.

Choi SH, Chang JS, Kim NK, Lim JS, Min BS, Hur H, Shin SJ, Ahn JB, Kim YB, Koom WS.

J Radiat Res. 2017 Jul 1;58(4):559-566. doi: 10.1093/jrr/rrw127.

32.

Identification of genetic susceptibility loci for intestinal Behçet's disease.

Kim SW, Jung YS, Ahn JB, Shin ES, Jang HW, Lee HJ, Il Kim T, Kim DY, Bang D, Kim WH, Cheon JH.

Sci Rep. 2017 Jan 3;7:39850. doi: 10.1038/srep39850.

33.

Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.

Heo H, Ahn JB, Lee HH, Kwon E, Yun JW, Kim H, Kang BC.

NMR Biomed. 2017 Feb;30(2). doi: 10.1002/nbm.3686. Epub 2016 Dec 28.

PMID:
28028868
34.

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H, Yamazaki K, Han SW, Wang W, Ahn JB, Deng Y, Cho SH, Ba Y, Lee KW, Zhang T, Satoh T, Buyse ME, Ryoo BY, Shen L, Sakamoto J, Kim TW.

Chin J Cancer. 2016 Dec 22;35(1):102. doi: 10.1186/s40880-016-0166-3.

35.

ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition.

Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC.

Biochem Pharmacol. 2017 Jan 1;123:73-84. doi: 10.1016/j.bcp.2016.11.005. Epub 2016 Nov 7.

PMID:
27832934
36.
37.
38.
39.

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.

Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, Ahn JB, Valencia RV, Krishnan S, Bilic A, Manojlovic N, Dong J, Guan X, Lofton-Day C, Jung AS, Vrdoljak E.

Br J Cancer. 2016 Nov 8;115(10):1206-1214. doi: 10.1038/bjc.2016.309. Epub 2016 Oct 13.

40.

Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.

Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ.

Ann Surg Oncol. 2017 Jan;24(1):227-235. doi: 10.1245/s10434-016-5613-5. Epub 2016 Oct 3.

PMID:
27699609
41.

Epidemiology and virologic investigation of human enterovirus 71 infection in the Republic of Korea from 2007 to 2012: a nationwide cross-sectional study.

Kim HJ, Hyeon JY, Hwang S, Lee YP, Lee SW, Yoo JS, Kang B, Ahn JB, Jeong YS, Lee JW.

BMC Infect Dis. 2016 Aug 18;16(1):425. doi: 10.1186/s12879-016-1755-0.

42.

Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors.

Yoon HI, Koom WS, Kim TH, Ahn JB, Jung M, Kim TI, Kim H, Shin SJ, Kim NK.

PLoS One. 2016 Aug 18;11(8):e0161475. doi: 10.1371/journal.pone.0161475. eCollection 2016.

43.

High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer.

Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC.

J Cancer Res Clin Oncol. 2016 Sep;142(9):2051-9. doi: 10.1007/s00432-016-2208-2. Epub 2016 Jul 22.

PMID:
27447697
44.

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.

Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS.

BMC Cancer. 2016 Jul 8;16:434. doi: 10.1186/s12885-016-2451-6.

45.

Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.

Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC.

Ann Surg. 2017 May;265(5):946-953. doi: 10.1097/SLA.0000000000001793.

46.

Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.

Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ.

Br J Cancer. 2016 Jun 28;115(1):25-33. doi: 10.1038/bjc.2016.161. Epub 2016 May 26.

47.

Activation and Recruitment of Regulatory T Cells via Chemokine Receptor Activation in Trichinella spiralis-Infected Mice.

Ahn JB, Kang SA, Kim DH, Yu HS.

Korean J Parasitol. 2016 Apr;54(2):163-71. doi: 10.3347/kjp.2016.54.2.163. Epub 2016 Apr 30.

48.

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.

Kim JH, Lee JS, Kim EJ, Park KH, Kim KH, Yi SY, Kim HS, Cho YJ, Shin KH, Ahn JB, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Noh SH, Rha SY, Kim HS.

Oncotarget. 2016 Apr 26;7(17):24549-58. doi: 10.18632/oncotarget.8240.

49.

Circumferential resection margin positivity after preoperative chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer: implication of boost radiotherapy to the involved mesorectal fascia.

Kim KH, Park MJ, Lim JS, Kim NK, Min BS, Ahn JB, Kim TI, Kim HG, Koom WS.

Jpn J Clin Oncol. 2016 Apr;46(4):316-22. doi: 10.1093/jjco/hyv208. Epub 2016 Jan 21.

50.

The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial.

Kim CW, Baek JH, Choi GS, Yu CS, Kang SB, Park WC, Lee BH, Kim HR, Oh JH, Kim JH, Jeong SY, Ahn JB, Baik SH.

Trials. 2016 Jan 19;17:34. doi: 10.1186/s13063-016-1164-0.

Supplemental Content

Support Center